Patients at the same pathological stage of esophageal cancer (EC) that received the same surgical therapy by the same surgeon may have distinct prognoses. The current study aimed to explore the possibility of differentially- expressed microRNAs (miRNAs) underlying this phenomenon. Samples were collected from EC patients at the same tumor node metastasis (TNM) stage but with different prognoses. Paracancerous normal tissues were taken as controls. The specimens were histopathologically analyzed. Differentially-expressed miRNAs were analyzed using real-time quantitative reverse transcription polymerase chain reaction. Compared with patients with poor prognosis, those with good prognosis exhibited 88 two-fold or more than two-fold increased miRNA fragments and 4 half-decreased miRNAs. The most noticeably up-regulated miRNAs included hsa-miR-31, hsa-miR- 196b, hsa-miR-652, hsa-miR-125a-5p, hsa-miR-146b, hsa-miR-200c, hsa-miR-23b, hsa-miR-29a, hsa-miR-186, hsa-miR-205, hsa-miR-376a, hsa-miR-410, hsa-miR-532-3p, and hsa-miR-598, whereas the most significantly- downregulated miRNAs were hsa-let-7e, hsa-miR-130b, and hsa-miR-103. EC patients at same TNM stage but with different prognoses show differentially-expressed miRNAs.

Download full-text PDF

Source
http://dx.doi.org/10.7314/apjcp.2013.14.1.139DOI Listing

Publication Analysis

Top Keywords

stage prognoses
12
esophageal cancer
8
tumor node
8
node metastasis
8
tnm stage
8
differentially-expressed mirnas
8
mirnas
6
patients
5
screening microrna
4
microrna patients
4

Similar Publications

Nasal spray treatments that inhibit the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry into nose and nasopharynx at early stages can be an appropriate approach to stop or delay the progression of the disease. We performed a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicentric, phase II clinical trial comparing the rate of hospitalization due to COVID-19 infection between azelastine 0.1% nasal spray and placebo nasal spray treatment groups.

View Article and Find Full Text PDF

The Potential of TRPA1 as a Therapeutic Target in Cancer-A Study Using Bioinformatic Tools.

Pharmaceuticals (Basel)

December 2024

Department of Anatomy, Biophysics and Physiology, Faculty of Biology, University of Bucharest, Spl. Independentei 91-95, 050095 Bucharest, Romania.

The expression of the transient receptor potential 1 (TRPA1) gene is increased in many solid tumours, and its function relates to inflammation, oxidative stress or the presence of toxic substances. However, little is known about the correlation of clinical parameters with patients' cancer stages, metastases and the degree of tumour infiltration by immune cells. We performed a bioinformatic analysis, using databases and public resources to investigate TRPA1 for many available samples.

View Article and Find Full Text PDF

CRISPR/Cas9 Technology Providing the Therapeutic Landscape of Metastatic Prostate Cancer.

Pharmaceuticals (Basel)

November 2024

Department of Biochemistry, College of Medicine, Gachon University, Incheon 21999, Republic of Korea.

Prostate cancer (PCa) is the most prevalent malignancy and the second leading cause of cancer-related death in men. Although current therapies can effectively manage the primary tumor, most patients with late-stage disease manifest with metastasis in different organs. From surgery to treatment intensification (TI), several combinations of therapies are administered to improve the prognosis of patients with metastatic PCa.

View Article and Find Full Text PDF

Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing (NGS) enables comprehensive genetic profiling of tumours, including non-driver alterations that offer prognostic insights. LB can be applied in both early-stage disease settings, for the diagnosis and monitoring of minimal residual disease (MRD), and advanced disease settings, for monitoring treatment response and understanding the mechanisms behind disease progression and tumour heterogeneity.

View Article and Find Full Text PDF

Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.

Int J Mol Sci

December 2024

Faculty of Medicine with the Division of Dentistry and Division of Medical Education in English, Medical University of Bialystok, 15-269 Bialystok, Poland.

Malignant melanoma is one of the most important dermatological neoplasms. The high mortality rate associated with this skin disease is primarily due to the occurrence of metastases, while the diagnosis and treatment of melanoma in its early stages has a favorable prognosis. Early detection is crucial because the success of treatment is directly related to the depth of cancerous growth.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!